GSK plc Reports Share Transaction
Ticker: GLAXF · Form: 6-K · Filed: Aug 15, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Aug 15, 2025 |
| Risk Level | low |
| Pages | 8 |
| Reading Time | 10 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-transaction, disclosure, foreign-private-issuer
TL;DR
GSK plc filed a 6-K on 8/15/25 reporting a transaction in its own shares.
AI Summary
GSK plc announced on August 15, 2025, that it has completed a transaction involving its own shares. The filing, a Form 6-K, is a report of a foreign private issuer and indicates GSK plc is acting through its corporate entity.
Why It Matters
This filing provides transparency regarding GSK's activities in managing its own stock, which can impact share count and potentially investor perception.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of share transactions and does not indicate any immediate financial distress or significant operational changes.
Key Players & Entities
- GSK plc (company) — Registrant
- August 2025 (date) — Reporting period
- 001-15170 (other) — Commission File Number
FAQ
What type of transaction did GSK plc report?
GSK plc reported a 'Transaction in own shares'.
What is the filing type and date?
The filing is a Form 6-K, filed as of August 15, 2025.
Is GSK plc a US-based company?
No, GSK plc is identified as a 'Foreign Private Issuer' and its principal executive office is in London, UK.
What is the Commission File Number for GSK plc?
The Commission File Number is 001-15170.
Does GSK plc file annual reports under Form 20-F or 40-F?
GSK plc indicates it files annual reports under cover of Form 20-F.
Filing Stats: 2,516 words · 10 min read · ~8 pages · Grade level 3 · Accepted 2025-08-15 06:32:46
Filing Documents
- a4241v.htm (6-K) — 5542KB
- 0001654954-25-009682.txt ( ) — 5543KB
From the Filing
IN OWN SHARES a4241v   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of August 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .                                     Transaction in own shares   GSK plc (the " Company ") announces today   acting through its corporate stockbroker, Merrill Lynch International (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase: 14 August 2025 Aggregate number of ordinary shares of  31¼  pence each purchased: 501,689 Lowest price paid per share (GBp): 1,401.50p Highest price paid per share (GBp): 1,415.50p Volume-weighted average price paid per share (GBp): 1,407.59p   The purchased shares will be held as Treasury shares.   Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 23,706,405 ordinary shares.   Following the above purchase, the Company will hold 241,840,788 ordinary shares in treasury and have 4,073,550,458 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,073,550,458. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is   5.94 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.   Schedule of Purchases Shares purchased:      GSK plc (ISIN: GB00BN7SWP63) D ate of purchases:     14 August 2025 Investment firm:         Merrill Lynch International   Aggregated information per trading venue: Venue Number of ordinary shares purchased Highest price paid (per ordinary share) (GBp) Lowest price paid (per ordinary share) (GBp) Volume weighted average price paid (per ordinary share) (GBp) London Stock Exchange (XLON) 501,689 1,415.50p 1,401.50p 1,407.59p CBOE (CHIX) 0 - - - CBOE (BATE) 0 - - -     Individual transactions: Number ofShares Price per Share (GBp) Tradingvenue Date oftransaction Time oftransaction Transaction reference number 11 1,415.00  XLON 14-Aug-2025 08:00:36 0XL06A0000000000ARCNVF 12 1,415.00  XLON 14-Aug-2025 08:00:36 0XL0610000000000ARCNNI 12 1,415.00  XLON 14-Aug-2025 08:00:36 0XL06A0000000000ARCNVE 13 1,415.00  XLON 14-Aug-2025 08:00:36 0XL0610000000000ARCNNG 13 1,415.00  XLON 14-Aug-2025 08:00:36 0XL06A0000000000ARCNVG 14 1,415.00  XLON 14-Aug-2025 08:00:36 0XL0610000000000ARCNNH 11 1,414.50  XLON 14-Aug-2025 08:00:57 0XL0640000000000ARCO1J 12 1,414.50  XLON 14-Aug-2025 08:00:57 0XL0611000000000ARCO2B 12 1,414.50  XLON 14-Aug-2025 08:00:57 0XL0640000000000ARCO1K 12 1,414.50  XLON 14-Aug-2025 08:00:57 0XL0670000000000ARCO2J 12 1,414.50  XLON 14-Aug-2025 08:00:57 0XL0670000000000ARCO2K 13 1,414.50  XLON 14-Aug-2025 08:00:57 0XL0611000000000ARCO29 13 1,414.50  XLON 14-Aug-2025 08:00:57 0XL0611000000000ARCO2A 13 1,414.50  XLON 14-Aug-2025 08:00:57 0XL0611000000000ARCO2C 13 1,414.50  XLON 14-Aug-2025 08:00:57 0XL0614000000000ARCO1A 13 1,414.50  XLON 14-Aug-2025 08: